Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.34 |
| ▸ | CLK2 | P49760 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020834 | 0.93 | PIK3C3 (0.35) | HTR2CKITABL1RETKDR | |
| SCHEMBL15060068 | 0.89 | KIT (0.34) | CLK2DYRK1AKITCLK3 | |
| SCHEMBL15036344 | 0.88 | CLK2 (0.38) | HTR2CCLK2DYRK1AKITIRAK4 | |
| SCHEMBL12745918 | 0.87 | CLK2 (0.39) | HTR2CCLK2DYRK1ACLK3ABL1 | |
| SCHEMBL15020476 | 0.85 | BRD4 (0.43) | HTR2CKITRETKDR | |
| SCHEMBL15020878 | 0.80 | CYP19A1 (0.40) | HTR2CCLK2DYRK1AKITCLK3 | |
| SCHEMBL15020536 | 0.79 | ORAI1 (0.49) | HTR2CKITRETKDRCHEK1 | |
| SCHEMBL15020674 | 0.78 | CYP2E1 (0.37) | HTR2CCLK2DYRK1AKITCLK3 | |
| SCHEMBL15020474 | 0.76 | CHEK1 (0.35) | CHEK1ACHE | |
| SCHEMBL15020471 | 0.76 | CYP2C9 (0.37) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | claimed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | claimed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | HTR2C 493/4885CLK2 3205/4885DYRK1A 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.